Kok-Yong Seng
Overview
Explore the profile of Kok-Yong Seng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurumurthy M, Verma R, Naftalin C, Hee K, Lu Q, Tan K, et al.
J Antimicrob Chemother
. 2017 Mar;
72(7):2012-2019.
PMID: 28333342
Background: Faropenem has in vitro activity against Mycobacterium tuberculosis (Mtb) and shows synergy with rifampicin. We tested this in a whole-blood bactericidal activity (WBA) trial. Methods: We randomized healthy volunteers...
2.
Seng K, Chen Y, Wang T, Ming Chai A, Yuen Fun D, Teo Y, et al.
Physiol Meas
. 2016 Mar;
37(4):485-502.
PMID: 26963194
Many longitudinal studies have collected serial body core temperature (T c) data to understand thermal work strain of workers under various environmental and operational heat stress environments. This provides the...
3.
Lee L, Seng K, Wang L, Yong W, Hee K, Soh T, et al.
PLoS One
. 2016 Jan;
11(1):e0147681.
PMID: 26808671
Background: Irinotecan toxicity correlates with UGT1A1 activity. We explored whether phenotyping UGT1A1 using a probe approach works better than current genotyping methods. Methods: Twenty-four Asian cancer patients received irinotecan as...
4.
Seng K, Hee K, Soon G, Chew N, Khoo S, Lee L
J Antimicrob Chemother
. 2015 Sep;
70(12):3298-306.
PMID: 26342028
Objectives: Rifampicin is a first-line anti-TB drug. The objectives of this analysis were to evaluate the population pharmacokinetics of rifampicin and its partly active metabolite, 25-deacetyl-rifampicin, with and without isoniazid,...
5.
Seng K, Hee K, Soon G, Chew N, Khoo S, Lee L
Antimicrob Agents Chemother
. 2015 Aug;
59(11):6791-9.
PMID: 26282412
In this study, we aimed to quantify the effects of the N-acetyltransferase 2 (NAT2) phenotype on isoniazid (INH) metabolism in vivo and identify other sources of pharmacokinetic variability following single-dose...
6.
Seng K, Hee K, Soon G, Sapari N, Soong R, Goh B, et al.
J Clin Pharmacol
. 2013 Nov;
54(2):215-24.
PMID: 24214410
We aim to evaluate the influence of covariates, including cytochrome P450 3A (CYP3A) genetic polymorphisms, on the pharmacokinetics of midazolam (MDZ) in Asian cancer patients, using a population pharmacokinetic approach....
7.
Seng K, Fan L, Lee H, Yong W, Goh B, Lee L
Ther Drug Monit
. 2011 Nov;
33(6):719-29.
PMID: 22105589
Background: Modafinil is a psychostimulant used to treat excessive sleepiness. The aim of this study was to develop a population pharmacokinetic model of modafinil and its major metabolites in Chinese...
8.
Wang L, Soon G, Seng K, Li J, Lee E, Yong E, et al.
Antimicrob Agents Chemother
. 2011 Jul;
55(9):4090-5.
PMID: 21746959
Raltegravir is a potent inhibitor of HIV integrase. Persistently high intracellular concentrations of raltegravir may explain sustained efficacy despite high pharmacokinetic variability. We performed a pharmacokinetic study of healthy volunteers....
9.
Chen K, Seng K
J Appl Toxicol
. 2011 Mar;
32(9):673-86.
PMID: 21433037
A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model has been developed for low, medium and high levels of soman intoxication in the rat, marmoset, guinea pig and pig. The primary...
10.
Seng K, Teo W, Fun C, Law Y, Lim C
Biopharm Drug Dispos
. 2010 Jun;
31(5-6):316-30.
PMID: 20578210
The objective was to develop a population pharmacokinetic-pharmacodynamic model of caffeine's psychomotor effects in healthy, non-habitual users of caffeine. Twenty Chinese males each received a single dose of 250 mg...